BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19190116)

  • 1. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
    Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
    Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of trabectedin in myxoid liposarcomas.
    Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
    Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas.
    Huang HY; Antonescu CR
    Ultrastruct Pathol; 2003; 27(4):217-26. PubMed ID: 12907366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
    Riggi N; Cironi L; Provero P; Suvà ML; Stehle JC; Baumer K; Guillou L; Stamenkovic I
    Cancer Res; 2006 Jul; 66(14):7016-23. PubMed ID: 16849546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
    Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
    Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
    Tornin J; Hermida-Prado F; Padda RS; Gonzalez MV; Alvarez-Fernandez C; Rey V; Martinez-Cruzado L; Estupiñan O; Menendez ST; Fernandez-Nevado L; Astudillo A; Rodrigo JP; Lucien F; Kim Y; Leong HS; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2018 Jan; 20(1):44-56. PubMed ID: 29190494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
    Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
    PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.
    Panagopoulos I; Lassen C; Isaksson M; Mitelman F; Mandahl N; Aman P
    Oncogene; 1997 Sep; 15(11):1357-62. PubMed ID: 9315104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
    Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
    Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myxoid liposarcoma with cartilaginous differentiation: identification of the same type II TLS-CHOP fusion gene transcript in both lipogenic and chondroid components.
    Wei YC; Li CF; Eng HL; Yeh MC; Lin CN; Huang HY
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):477-80. PubMed ID: 18091394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
    Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M
    Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.
    Hisaoka M; Tsuji S; Morimitsu Y; Hashimoto H; Shimajiri S; Komiya S; Ushijima M
    Diagn Mol Pathol; 1998 Apr; 7(2):96-101. PubMed ID: 9785008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas].
    Xiang H; Wang J; Sun MH; Lu L; Shui RH; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):28-32. PubMed ID: 15796878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.
    Olofsson A; Willén H; Göransson M; Engström K; Meis-Kindblom JM; Stenman G; Kindblom LG; Aman P
    Int J Oncol; 2004 Nov; 25(5):1349-55. PubMed ID: 15492825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.